AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 7342331
Drug: Praziquantel 25
RxNorm normalized name: PRAZIQUANTEL 25 kg in 25 kg POWDER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Praziquantel 25 mg per kg body weight bid for one day (Group III)
Trial: 7342331
Drug: Praziquantel 25
RxNorm normalized name: PRAZIQUANTEL 25 kg in 25 kg POWDER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Praziquantel 25 mg per kg body weight in a single dose (Group IV)
Trial: 7342331
Drug: Praziquantel 40
RxNorm normalized name: PRAZIQUANTEL 40 mg in 1 mL ORAL SOLUTION [A Vial]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Praziquantel 40 mg per kg body weight in a single dose (Group V)
Trial: 26761398
Drug: Cognitive therapy
RxNorm normalized name: cognitive therapy software
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive therapy sessions analysis
Trial: 22630801
Drug: Cognitive remediation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive remediation (CR) therapy (12 sessions of computer-assisted CR)
Trial: 22630801
Drug: Cognitive remediation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive remediation (CR) therapy
Trial: 12523867
Drug: Testosterone cypionate
RxNorm normalized name: Testosterone Cypionate
DrugBank: Testosterone cypionate (DB13943)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone cypionate 100 mg/week
Trial: 12523867
Drug: Testosterone cypionate
RxNorm normalized name: Testosterone Cypionate
DrugBank: Testosterone cypionate (DB13943)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone cypionate 200 mg/week
Trial: 9155505
Drug: Selenomethionine (SeMet)
RxNorm normalized name: selenomethionine
DrugBank: Selenomethionine (DB11142)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Selenomethionine (SeMet) 200 micrograms daily
Trial: 9155505
Drug: Selenate (Se-enriched
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selenate (Se-enriched yeast) 200 micrograms daily
Trial: 3612550
Drug: Domperidone (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Domperidone (0.4 mg/kg)
Trial: 29243443
Drug: CC+Gn+Dingkun Dan
RxNorm normalized name: colloidal oatmeal
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CC+Gn+Dingkun Dan
Trial: 29243443
Drug: CC+Gn+HCG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CC+Gn+HCG
Trial: 25205409
Drug: US-guided single-injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: US-guided single-injection femoral nerve block with 40 ml of 0.5% bupivacaine and 1:200,000 epinephrine (Group F)
Trial: 23060723
Drug: Macular laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Macular laser photocoagulation following intravitreal injection of triamcinolone acetonide (IVTA)
Trial: 23060723
Drug: Intravitreal injection
RxNorm normalized name: Eylea 2 MG per 0.05 ML Intravitreal Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal injection of triamcinolone acetonide (IVTA) alone
Trial: 20214324
Drug: Diclofenac sodium
RxNorm normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Diclofenac sodium dual release enteric-coated capsules and Benzbromarone (Control)
Trial: 14985171
Drug: Platelet-neutrophil conjugate
RxNorm normalized name: platelet glycoprotein VI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platelet-neutrophil conjugate formation induced by thrombin receptor activating peptide (TRAP)
Trial: 7512299
Drug: Three TUHT
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three TUHT treatments
Trial: 7512299
Drug: Six TUHT
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Six TUHT treatments
Trial: 1320621
Drug: 1.5 mm
RxNorm normalized name: blade lancet, safety 1.5 mm X 2 mm MISCELL EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 mm intramedullary rod (polyglycolide implants)
Trial: 82735
Drug: Enkephalin analogue
RxNorm normalized name: gonadotropin releasing factor analog-diphtheria toxoid conjugate Injectable Solution [Improvest]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enkephalin analogue [D‐Ala2, MePhe4, Met(o)‐ol] enkephalin (DAMME) administered intravenously
Trial: 82735
Drug: Prior administration
RxNorm normalized name: Priorix
DrugBank: Rubella virus vaccine (DB10317)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prior administration of the opiate antagonist, naloxone
Trial: 21303403
Drug: Systemic amoxicillin
RxNorm normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Systemic amoxicillin (AMX) 500mg + metronidazole (MET) 250mg, t.i.d. for 10 days
Trial: 17122107
Drug: 2.5 mg
RxNorm normalized name: biotin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg lutein
Trial: 17122107
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg lutein
Trial: 17478338
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg lutein
Trial: 17122107
Drug: All doses
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All doses of lutein
Trial: 2962529
Drug: Thiamphenicol 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiamphenicol 2.5 g orally
Trial: 2962529
Drug: Spectinomycin 2
RxNorm normalized name: spectinomycin 2 g intramuscular powder for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spectinomycin 2 g intramuscularly
Trial: 24094979
Drug: Standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care plus cognitive-behavioral therapy (STD + CBT)
Trial: 12243656
Drug: 10 cc
RxNorm normalized name: CC
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 cc of 2% intrarectal lidocaine gel (Xylocaine 2% jelly, Astra Pharma Inc.) 5 to 10 minutes before the procedure
Trial: 12243656
Drug: 10 cc
RxNorm normalized name: CC
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 cc of lubricating gel
Trial: 2305099
Drug: 30 mL
RxNorm normalized name: Vial M/T 30 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mL of contrast material injected at the level of the external iliac artery (EIA)
Trial: 2305099
Drug: 60 mL
RxNorm normalized name: Disposable Nurser 60 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mL of contrast material injected at the level of the EIA
Trial: 2305099
Drug: 120 mL
RxNorm normalized name: 120 ML Infugem 10 MG/ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120 mL of contrast material injected at the level of the aortic bifurcation and 60 mL injected at the level of the EIA
Trial: 2305099
Drug: 60 mL
RxNorm normalized name: Disposable Nurser 60 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mL injected at the level of the EIA with inflow occlusion
Trial: 2305099
Drug: 60 mL
RxNorm normalized name: Disposable Nurser 60 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mL injected at the level of the EIA without inflow occlusion
Trial: 7005123
Drug: Furosemide +
RxNorm normalized name: Furosemide
DrugBank: Furosemide (DB00695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Furosemide + Triamterene (80 + 100 mg)
Trial: 28338504
Drug: Protective group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protective group (tidal volume; 6 mL/kg predicted body weight, 6 cm H2O positive end-expiratory pressure with recruitment maneuvers)
Trial: 28338504
Drug: Conventional group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional group (10 mL/kg predicted body weight, no positive end-expiratory pressure)
Trial: 26657997
Drug: 15-mcg unadjuvanted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15-mcg unadjuvanted clade 2 vaccine
Trial: 26657997
Drug: 90-mcg unadjuvanted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 90-mcg unadjuvanted clade 2 vaccine
Trial: 26657997
Drug: 90-mcg dosage
RxNorm normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 90-mcg dosage in unprimed recipients
Trial: 26657997
Drug: Alum-adjuvanted clade
RxNorm normalized name: alum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alum-adjuvanted clade 1 H5N1 vaccines
Trial: 26657997
Drug: Non-adjuvanted clade
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-adjuvanted clade 1 H5N1 vaccines
Trial: 22584689
Drug: Lornoxicam 16
RxNorm normalized name: Lornoxicam 16 mg prolonged-release oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lornoxicam 16 mg then 8 mg after 12 h
Trial: 21097402
Drug: Routine western
RxNorm normalized name: western larch pollen extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine western medication
Trial: 2148177
Drug: cetirizine 5
RxNorm normalized name: cetirizine 5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cetirizine 5 mg, 10 mg, or 20 mg
Trial: 2148177
Drug: hydroxyzine 25
RxNorm normalized name: hydroxyzine 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hydroxyzine 25 mg
Trial: 30632972
Drug: BlueStar mobile
RxNorm normalized name: Chamaemelum nobile extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BlueStar mobile app for 6 months (immediate treatment group)
Trial: 25754454
Drug: Intravesical 0.1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravesical 0.1% oxybutynin hydrochloride (10 ml, three times per day for 28 days)
Trial: 25754454
Drug: Oral 5
RxNorm normalized name: Syringe Oral 5cc
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral 5 mg oxybutynin hydrochloride (three times per day for 28 days)
Trial: 25754454
Drug: Oral 5
RxNorm normalized name: Syringe Oral 5cc
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral 5 mg oxybutynin hydrochloride
Trial: 25031529
Drug: Alpha-blocker plus
RxNorm normalized name: ALPHA BLOCKERS/RELATED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpha-blocker plus antidiuretic agent
Trial: 25031529
Drug: Alpha-blocker plus
RxNorm normalized name: ALPHA BLOCKERS/RELATED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpha-blocker plus anticholinergic agent
Trial: 25031529
Drug: Alpha-blocker
RxNorm normalized name: ALPHA BLOCKERS/RELATED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpha-blocker
Trial: 12412821
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronic acid 4 mg/5 min
Trial: 12412821
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronic acid (all doses)
Trial: 6388080
Drug: Noradrenaline (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Noradrenaline (8 mg in 100 ml cold saline)
Trial: 9279213
Drug: Inhaled ET-1
RxNorm normalized name: isoetharine 1 % Inhalation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled ET-1 (doubling dose range, 0.96 to 15.36 nmol)
Trial: 9279213
Drug: Methacholine (doubling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methacholine (doubling dose range, 0.33 to 21.0 mumol)
Trial: 30457060
Drug: Gonadotrophin-releasing hormone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gonadotrophin-releasing hormone agonist (GnRHa)
Trial: 3729714
Drug: Low-dose subcutaneous
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose subcutaneous heparin therapy
Trial: 25274610
Drug: Dasatinib (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dasatinib (100 mg) alone
Trial: 25274610
Drug: Dasatinib (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dasatinib (100 mg) with 1500 mg BHCl after rabeprazole pretreatment
Trial: 22462626
Drug: Vardenafil 5
RxNorm normalized name: vardenafil 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vardenafil 5 mg/day
Trial: 22462626
Drug: Vardenafil 10
RxNorm normalized name: vardenafil 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vardenafil 10 mg/day
Trial: 22462626
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no PDE5 inhibitors)
Trial: 12050248
Drug: Growth Hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth Hormone (GH) at a dose of 12.5 microg/kg per day for 12 months
Trial: 10332946
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of naps and modafinil
Trial: 1712266
Drug: Cilazapril and
RxNorm normalized name: cilazapril and diuretics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cilazapril and Propranolol combination
Trial: 27579803
Drug: MTPT and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MTPT and medicine ball exercises
Trial: 25799801
Drug: Fentanyl 20
RxNorm normalized name: fentaNYL 200 mcg buccal film
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl 20 microgram (0.4 ml) added to 0.5% bupivacaine heavy 2 ml (Group B)
Trial: 25799801
Drug: 0.5% bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% bupivacaine heavy 2.4 ml (Group A)
Trial: 17200838
Drug: MK-0524 25
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-0524 25 mg
Trial: 17200838
Drug: MK-0524 100
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-0524 100 mg
Trial: 12365909
Drug: Verteporfin therapy
RxNorm normalized name: Verteporfin
DrugBank: Verteporfin (DB00460)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Verteporfin therapy (original assignment)
Trial: 16495883
Drug: Biological supplement
RxNorm normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biological supplement (FloRelax®, Sanofi Winthrop) for 6 weeks
Trial: 8087928
Drug: Chelation therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chelation therapy (EDTA)
Trial: 2571759
Drug: Pyrimethamine (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pyrimethamine (25 mg weekly for suppressive prophylaxis)
Trial: 2571759
Drug: Pyrimethamine (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pyrimethamine (25 mg weekly after chloroquine 25 mg/kg)
Trial: 2571759
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no prophylaxis after chloroquine 25 mg/kg)
Trial: 16223747
Drug: hGH treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hGH treatment (4 IU/m2/day for two years)
Trial: 11054340
Drug: Topical dexamethasone
RxNorm normalized name: dexamethasone Topical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical dexamethasone (0.1%) administered four times daily
Trial: 11054340
Drug: Topical dexamethasone
RxNorm normalized name: dexamethasone Topical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical dexamethasone (0.1%) administered twice daily
Trial: 23808594
Drug: Nimodipine AP
RxNorm normalized name: Nimodipine
DrugBank: Nimodipine (DB00393)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nimodipine AP (Tropocer®) 90 mg once daily
Trial: 23808594
Drug: Nimodipine (Nimotop®)
RxNorm normalized name: Nimodipine
DrugBank: Nimodipine (DB00393)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nimodipine (Nimotop®) 30 mg three times daily
Trial: 18272244
Drug: Androgenic anabolic
RxNorm normalized name: ANDROGENS/ANABOLICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Androgenic anabolic steroids
Trial: 18272244
Drug: Drug-free bodybuilders
RxNorm normalized name: HERBAL BODYBUILDING CAP/TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug-free bodybuilders
Trial: 28483498
Drug: 100% RDA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100% RDA (0.8g·kg‐1·d‐1) plus placebo injections
Trial: 28483498
Drug: 100% RDA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100% RDA (0.8g·kg‐1·d‐1) plus 100mg testosterone enanthate injections
Trial: 28483498
Drug: 163% RDA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 163% RDA (1.3g·kg‐1·d‐1) plus placebo injections
Trial: 28483498
Drug: 163% RDA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 163% RDA (1.3g·kg‐1·d‐1) plus testosterone injections
Trial: 23904400
Drug: Chemotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy plus leuprolide acetate
Trial: 21707189
Drug: Prize contingency
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prize contingency management (CM) treatment
Trial: 2568639
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg zuclopenthixol daily
Trial: 2568639
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg haloperidol in the morning and 5 mg levomepromazine in the evening
Trial: 893737
Drug: Intravenous hydralazine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous hydralazine, 0.15 mg/kg
Trial: 893737
Drug: Intravenous propranolol,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous propranolol, 0.1 mg/kg
Trial: 893737
Drug: Intravenous hydralazine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous hydralazine, 0.15 mg/kg after phentolamine infusion (0.01 or 0.02 mg/kg per minute)
Trial: 893737
Drug: Intravenous hydralazine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous hydralazine, 0.30 mg/kg
Trial: 893737
Drug: Intravenous hydralazine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous hydralazine, 0.60 mg/kg
Trial: 17729060
Drug: Salmeterol (a
RxNorm normalized name: salmeterol (as xinafoate)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salmeterol (a long-acting β2-agonist) in combination with fluticasone propionate (an inhaled corticosteroid)
Trial: 17729060
Drug: Tiotropium bromide
RxNorm normalized name: Tiotropium Bromide
DrugBank: Tiotropium (DB01409)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tiotropium bromide (an anticholinergic bronchodilator)
Trial: 11818765
Drug: loratadine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: loratadine (20 mg)
Trial: 11818765
Drug: ranitidine (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ranitidine (300 mg)
Trial: 8678246
Drug: Magnesium sulphate
RxNorm normalized name: Magnesium sulphate
DrugBank: Magnesium (DB14513)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium sulphate (40 mg.kg‐1)
Trial: 25775661
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of trichloroacetic acid (TCA) 50% solution once weekly
Trial: 22177370
Drug: Murraya koenigii
RxNorm normalized name: MURRAYA KOENIGII WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Murraya koenigii and Tribulus terrestris-based oral formulation (2 capsules BID for 12 weeks)
Trial: 22177370
Drug: Tamsulosin (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamsulosin (400 μg once daily for 12 weeks)
Trial: 10886048
Drug: Sucralfate 1
RxNorm normalized name: sucralfate 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sucralfate 1 g t.d.s., amoxycillin 500 mg t.d.s., and clarithromycin 400 mg b.d. (SAC regimen)
Trial: 10886048
Drug: Lansoprazole 30
RxNorm normalized name: lansoprazole 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole 30 mg o.m. with the same antimicrobial medications (LAC regimen)
Trial: 2871860
Drug: Two drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two drug regimen: vincristine 2 mg m‐2 (maximum 2mg) followed by methotrexate 200 mgm‐2, given every three weeks for 54 weeks.
Trial: 2871860
Drug: Three drug
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three drug regimen: vincristine-methotrexate treatment alternating every three weeks with doxorubicin 60 mg m‐2 for 54 weeks.
Trial: 31258136
Drug: 10-day bismuth-containing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10-day bismuth-containing quadruple therapy (BQT)
Trial: 25074637
Drug: Dihydrexidine (DAR-0100A)
RxNorm normalized name: Magnesium dihydroxide
DrugBank: Dihydrexidine (DB12890)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dihydrexidine (DAR-0100A) 15 mg/150 ml of normal saline administered intravenously over 30 min
Trial: 19949360
Drug: Pentavalent human-bovine
RxNorm normalized name: human-bovine reassortant rotavirus strain G1 vaccine / human-bovine reassortant rotavirus strain G2 vaccine / human-bovine reassortant rotavirus strain G3 vaccine / human-bovine reassortant rotavirus strain G4 vaccine / human-bovine reassortant rotavirus strain P1A[8] vaccine Oral Suspension [RotaTeq]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentavalent human-bovine reassortant rotavirus vaccine
Trial: 16391891
Drug: Pamidronate (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pamidronate (1 mg/kg)
Trial: 16391891
Drug: Synthetic human
RxNorm normalized name: Synthetic human secretin
DrugBank: Secretin human (DB09532)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Synthetic human calcitonin (1.5 mg)
Trial: 15220685
Drug: Esomeprazole 40
RxNorm normalized name: esomeprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole 40 mg once daily, amoxicillin 1 g, clarithromycin 500 mg (EAC1 group, n = 52)
Trial: 15220685
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg, amoxicillin 1 g, clarithromycin 500 mg (OAC group, n = 52)
Trial: 15220685
Drug: Esomeprazole 40
RxNorm normalized name: esomeprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole 40 mg, amoxicillin 1 g, clarithromycin 500 mg (EAC2 group, n = 52)
Trial: 8384011
Drug: Meglumine antimonate
RxNorm normalized name: meglumine antimonate
DrugBank: Meglumine antimoniate (DB13732)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meglumine antimonate (10 mg of antimony/kg intramuscularly, twice a day for 20 days)